/
/
ุงุฑุชูุงุน ุงููุญุต ุงูุชุตููุฑ ุงูู
ุญุชูู ูุชุญุฏูุฏ ุงูุจูุชูููููู
ุงูุณู
ูู
ุงูุนุตุจูุฉ ุงูู
ุงูุนูู
JoVE ๋น๋์ค๋ฅผ ํ์ฉํ์๋ ค๋ฉด ๋์๊ด์ ํตํ ๊ธฐ๊ด ๊ตฌ๋
์ด ํ์ํฉ๋๋ค. ์ ์ฒด ๋น๋์ค๋ฅผ ๋ณด์๋ ค๋ฉด ๋ก๊ทธ์ธํ๊ฑฐ๋ ๋ฌด๋ฃ ํธ๋ผ์ด์ผ์ ์์ํ์ธ์.
1Perkin Elmer Inc., 2Henry M. Jackson Foundation, 3The Geneva Foundation, 4ORISE, 5Frederick National Laboratory for Cancer Research, 6Division of Molecular and Translational Sciences,US Army Medical Research Institute of Infectious Diseases, 7DoD Biotechnology High Performance Computing Software Applications Institute (BHSAI), Telemedicine and Advanced Technology Research Center (TATRC),US Army Medical Research and Materiel Command (USAMRMC)
Chapters
- 00:05Title
- 02:35Compound Administration and Intoxication with BoNT/A
- 05:46Immunostaining
- 08:08Image Acquisition
- 09:47Image Analysis
- 10:42Results: Data Visualization
- 12:57Conclusion
Botulinum neurotoxin is one of the most potent toxins among Category-A biothreat agents, yet a post-exposure therapeutic is not available. The high content imaging approach is a powerful methodology for identifying novel inhibitors as it enables multiparameter screening using biologically relevant motor neurons, the primary target of this toxin.
